[go: up one dir, main page]

WO2009028639A1 - 抗ｅｐｈａ２抗体 - Google Patents

抗ｅｐｈａ２抗体 Download PDF

Info

Publication number
WO2009028639A1
WO2009028639A1 PCT/JP2008/065486 JP2008065486W WO2009028639A1 WO 2009028639 A1 WO2009028639 A1 WO 2009028639A1 JP 2008065486 W JP2008065486 W JP 2008065486W WO 2009028639 A1 WO2009028639 A1 WO 2009028639A1
Authority
WO
WIPO (PCT)
Prior art keywords
hybridoma
antibody
produced
ferm
epha2 antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/065486
Other languages
English (en)
French (fr)
Inventor
Jun Hasegawa
Toshiaki Ohtsuka
Atsushi Urano
Junko Yamaguchi
Toshinori Agatsuma
Kaori Nakahara
Takeshi Takizawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN200880114621.5A priority Critical patent/CN101848998B/zh
Priority to LTEP08828482.3T priority patent/LT2199390T/lt
Priority to RU2010111896/10A priority patent/RU2525133C2/ru
Priority to AU2008292352A priority patent/AU2008292352B2/en
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Priority to JP2009530190A priority patent/JP5312333B2/ja
Priority to KR1020157008278A priority patent/KR101561417B1/ko
Priority to KR1020107004260A priority patent/KR101521668B1/ko
Priority to KR1020157008277A priority patent/KR101561416B1/ko
Priority to ES08828482.3T priority patent/ES2618316T3/es
Priority to MX2010002248A priority patent/MX2010002248A/es
Priority to HRP20170407TT priority patent/HRP20170407T1/hr
Priority to DK08828482.3T priority patent/DK2199390T3/en
Priority to KR1020147036821A priority patent/KR101561403B1/ko
Priority to BRPI0816094 priority patent/BRPI0816094A2/pt
Priority to SI200831748A priority patent/SI2199390T1/sl
Priority to CA2698146A priority patent/CA2698146C/en
Priority to EP08828482.3A priority patent/EP2199390B1/en
Priority to NZ583966A priority patent/NZ583966A/en
Publication of WO2009028639A1 publication Critical patent/WO2009028639A1/ja
Priority to ZA2010/01340A priority patent/ZA201001340B/en
Priority to US12/713,041 priority patent/US8449882B2/en
Priority to IL204211A priority patent/IL204211A/en
Anticipated expiration legal-status Critical
Priority to US13/899,996 priority patent/US9150657B2/en
Priority to US14/875,360 priority patent/US20160031987A1/en
Priority to CY20171100336T priority patent/CY1118763T1/el
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

細胞の癌化及び／又は腫瘍細胞増殖抑制活性を有する抗体等を提供すること。 ハイブリドーマＳＨ３４８－１（ＦＥＲＭ　ＢＰ－１０８３６）又はハイブリドーマＳＨ３５７－１（ＦＥＲＭ　ＢＰ－１０８３７）が産生する抗体によって認識されるエピトープを認識する抗体、ハイブリドーマＳＨ３４８－１又はハイブリドーマＳＨ３５７－１が産生する抗体、ハイブリドーマＳＨ３４８－１又はハイブリドーマＳＨ３５７－１が産生する抗体をヒト化した抗体、該抗体を有効成分として含有する医薬等の提供。
PCT/JP2008/065486 2007-08-30 2008-08-29 抗ｅｐｈａ２抗体 Ceased WO2009028639A1 (ja)

Priority Applications (24)

Application Number Priority Date Filing Date Title
DK08828482.3T DK2199390T3 (en) 2007-08-30 2008-08-29 ANTI-EphA2 ANTIBODY
RU2010111896/10A RU2525133C2 (ru) 2007-08-30 2008-08-29 Антитело к epha2
AU2008292352A AU2008292352B2 (en) 2007-08-30 2008-08-29 Anti-EPHA2 antibody
BRPI0816094 BRPI0816094A2 (pt) 2007-08-30 2008-08-29 Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo.
JP2009530190A JP5312333B2 (ja) 2007-08-30 2008-08-29 抗ｅｐｈａ２抗体
KR1020157008278A KR101561417B1 (ko) 2007-08-30 2008-08-29 항ｅｐｈａ２ 항체
KR1020107004260A KR101521668B1 (ko) 2007-08-30 2008-08-29 항ｅｐｈａ２ 항체
KR1020157008277A KR101561416B1 (ko) 2007-08-30 2008-08-29 항ｅｐｈａ２ 항체
LTEP08828482.3T LT2199390T (lt) 2007-08-30 2008-08-29 Anti-epha2 antikūnas
MX2010002248A MX2010002248A (es) 2007-08-30 2008-08-29 Anticuerpos anti-epha2.
HRP20170407TT HRP20170407T1 (hr) 2007-08-30 2008-08-29 Anti-epha2 anitijelo
KR1020147036821A KR101561403B1 (ko) 2007-08-30 2008-08-29 항ｅｐｈａ２ 항체
ES08828482.3T ES2618316T3 (es) 2007-08-30 2008-08-29 Anticuerpo anti EPHA2
CN200880114621.5A CN101848998B (zh) 2007-08-30 2008-08-29 抗epha2抗体
SI200831748A SI2199390T1 (sl) 2007-08-30 2008-08-29 Proti-epha2 protitelo
CA2698146A CA2698146C (en) 2007-08-30 2008-08-29 Anti-epha2 antibody
EP08828482.3A EP2199390B1 (en) 2007-08-30 2008-08-29 Anti-epha2 antibody
NZ583966A NZ583966A (en) 2007-08-30 2008-08-29 Anti-epha2 antibody
ZA2010/01340A ZA201001340B (en) 2007-08-30 2010-02-24 Anti-epha2 antibody
US12/713,041 US8449882B2 (en) 2007-08-30 2010-02-25 Anti-EPHA2 antibody
IL204211A IL204211A (en) 2007-08-30 2010-02-28 2epha antidote, a drug containing it and its uses
US13/899,996 US9150657B2 (en) 2007-08-30 2013-05-22 Anti-EPHA2 antibody
US14/875,360 US20160031987A1 (en) 2007-08-30 2015-10-05 Anti-epha2 antibody
CY20171100336T CY1118763T1 (el) 2007-08-30 2017-03-16 Αντισωμα αντι-ερηα2

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007224007 2007-08-30
JP2007-224007 2007-08-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/713,041 Continuation-In-Part US8449882B2 (en) 2007-08-30 2010-02-25 Anti-EPHA2 antibody

Publications (1)

Publication Number Publication Date
WO2009028639A1 true WO2009028639A1 (ja) 2009-03-05

Family

ID=40387351

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/065486 Ceased WO2009028639A1 (ja) 2007-08-30 2008-08-29 抗ｅｐｈａ２抗体

Country Status (26)

Country Link
US (3) US8449882B2 (ja)
EP (1) EP2199390B1 (ja)
JP (2) JP5312333B2 (ja)
KR (4) KR101521668B1 (ja)
CN (1) CN101848998B (ja)
AU (1) AU2008292352B2 (ja)
BR (1) BRPI0816094A2 (ja)
CA (1) CA2698146C (ja)
CO (1) CO6180469A2 (ja)
CY (1) CY1118763T1 (ja)
DK (1) DK2199390T3 (ja)
ES (1) ES2618316T3 (ja)
HR (1) HRP20170407T1 (ja)
HU (1) HUE032301T2 (ja)
IL (1) IL204211A (ja)
LT (1) LT2199390T (ja)
MX (1) MX2010002248A (ja)
MY (1) MY150621A (ja)
NZ (1) NZ583966A (ja)
PL (1) PL2199390T3 (ja)
PT (1) PT2199390T (ja)
RU (1) RU2525133C2 (ja)
SI (1) SI2199390T1 (ja)
TW (1) TWI443109B (ja)
WO (1) WO2009028639A1 (ja)
ZA (1) ZA201001340B (ja)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012008397A1 (ja) * 2010-07-12 2012-01-19 第一三共株式会社 抗ｅｐｈａ２抗体及びその用途
AU2011280893B2 (en) * 2010-07-22 2014-12-04 The Regents Of The University Of California Anti-tumor antigen antibodies and methods of use
WO2018135653A1 (ja) 2017-01-23 2018-07-26 学校法人東洋大学 抗ｅｐｈａ２抗体及びこれを用いたｅｐｈａ２の免疫学的検出
WO2020050406A1 (ja) 2018-09-06 2020-03-12 第一三共株式会社 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート
WO2022163846A1 (ja) 2021-02-01 2022-08-04 第一三共株式会社 抗体－免疫賦活化剤コンジュゲートの新規製造方法
WO2022191313A1 (ja) 2021-03-12 2022-09-15 第一三共株式会社 糖鎖及び糖鎖を含む医薬品の製造方法
CN115505041A (zh) * 2021-06-22 2022-12-23 北京免疫方舟医药科技有限公司 抗EphA2抗体及其应用
WO2023167238A1 (ja) 2022-03-02 2023-09-07 第一三共株式会社 Ｆｃ含有分子の製造方法
WO2024053574A1 (ja) 2022-09-09 2024-03-14 第一三共株式会社 新規なオリゴ糖、該オリゴ糖の製造中間体、及びそれらの製造方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
EP2446895A1 (en) 2010-10-01 2012-05-02 Stemgen S.P.A. EPH receptor expression in tumor stem cells
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
CA2830349C (en) 2011-03-17 2019-07-16 The University Of Birmingham Re-directed immunotherapy
JP5875054B2 (ja) 2013-02-13 2016-03-02 国立大学法人 東京大学 がんの検査方法及び検査用キット
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
CN115873110A (zh) * 2016-04-14 2023-03-31 刘扶东 抑制scube2，一种新颖vegfr2辅助受体，抑制肿瘤血管发生
US10626184B2 (en) 2016-06-09 2020-04-21 Omeros Corporation Monoclonal antibodies, compositions and methods for detecting mucin-like protein (MLP) as a biomarker for ovarian and pancreatic cancer
US11421032B2 (en) * 2017-05-22 2022-08-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for inhibition of MICA/B shedding
CN109879965B (zh) * 2017-12-06 2022-11-11 北京科立思维生物科技有限公司 抗epha2单链抗体、抗cd3e单链抗体及融合蛋白及其应用
US12448426B2 (en) 2018-05-17 2025-10-21 St. Jude Children's Research Hospital, Inc. Chimeric antigen receptors with MYD88 and CD40 costimulatory domains
KR20210105890A (ko) 2018-12-17 2021-08-27 레비토프 리미티드 트윈 면역 세포 인게이저
EP4301785A4 (en) 2021-03-05 2025-04-23 Atreca, Inc. EPHA2 ANTIBODIES
KR102795760B1 (ko) 2021-05-25 2025-04-15 주식회사 박셀바이오 모노바디 기반 키메라 항원 수용체 및 이를 포함하는 면역 세포

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007861A1 (en) 1988-12-28 1990-07-26 Protein Design Labs, Inc. CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
WO1995001438A1 (en) 1993-06-30 1995-01-12 Medical Research Council Sbp members with a chemical moiety covalently bound within the binding site; production and selection thereof
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
WO2001005950A2 (en) 1999-07-20 2001-01-25 Morphosys Ag Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
WO2002031140A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions
WO2003094859A2 (en) 2002-05-10 2003-11-20 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
WO2004061104A2 (en) 2003-01-07 2004-07-22 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
WO2006084226A2 (en) 2005-02-04 2006-08-10 Raven Biotechnologies, Inc. Antibodies that bind to epha2 and methods of use thereof
WO2007030642A2 (en) * 2005-09-07 2007-03-15 Medimmune, Inc. Toxin conjugated eph receptor antibodies

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2312316A1 (en) 1999-08-17 2011-04-20 Purdue Research Foundation Anti-EPHA2 antibodies as a cancer diagnostic
DE60027768T2 (de) 1999-08-17 2007-04-05 Purdue Research Foundation, West Lafayette Behandlung von metastatischer krankheit
CN102805868A (zh) 2000-03-31 2012-12-05 普渡研究基金会 用配体-免疫原缀合物治疗的方法
WO2002000728A2 (en) 2000-06-26 2002-01-03 Gpc Biotech Inc. Methods and compositions for isolating biologically active antibodies
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
WO2002099313A1 (fr) 2001-06-05 2002-12-12 Valeo Dispositif de verrouillage des pignons de transmission
EP1423428B2 (en) 2001-06-20 2012-11-14 Fibron Ltd. Antibodies that block fgfr3 activation, methods of screening for and uses thereof
CA2452578A1 (en) 2001-07-03 2003-01-16 The Hospital For Sick Children Ephrin and eph receptor mediated immune modulation
FR2838742B1 (fr) 2002-04-23 2004-07-09 Inst Nat Sante Rech Med Epitopes t de l'antigene epha2
AU2004293034B2 (en) * 2002-05-10 2012-02-02 Medimmune, Llc EphA2 agonistic monoclonal antibodies and methods of use thereof
ES2377720T3 (es) 2002-05-10 2012-03-30 Purdue Research Foundation Anticuerpos monoclonales agon�?sticos epha2 y métodos de uso de los mismos.
US20050152899A1 (en) 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
CA2486615A1 (en) 2002-05-23 2003-12-04 Purdue Research Foundation Low molecular weight protein tyrosine phosphatase (lmw-ptp) as a diagnostic and therapeutic target
US7326552B1 (en) 2002-06-21 2008-02-05 Takeda San Diego, Inc. Wild-type kinase domain of human Ephrin receptor A2 (EPHA2) and crystallization thereof
JP2006507256A (ja) 2002-09-24 2006-03-02 ザ バーナム インスティチュート Ｅｐｈ受容体活性を調節する新規薬剤
EP1852441B1 (en) 2002-09-24 2012-03-28 The Burnham Institute Agents that modulate EPH receptor activity
AU2003900541A0 (en) 2003-02-07 2003-02-20 Ludwig Institute For Cancer Research Modulation of cell adhesion and tumour cell metastasis
WO2004092343A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
AU2004229543A1 (en) 2003-04-11 2004-10-28 Medimmune, Llc EphA2 and non-neoplastic hyperproliferative cell disorders
CA2521826C (en) 2003-04-11 2013-08-06 Jennifer L. Reed Recombinant il-9 antibodies and uses thereof
JP4838720B2 (ja) 2003-05-13 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 転移および転移がもたらす骨格関連現象を調節する方法
US20050147593A1 (en) 2003-05-22 2005-07-07 Medimmune, Inc. EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders
DE602004025101D1 (de) 2003-05-31 2010-03-04 Micromet Ag Humane anti-humane cd3-bindungsmoleküle
US20050009033A1 (en) 2003-07-08 2005-01-13 The Regents Of The University Of California Breast cancer genes
WO2005016381A2 (en) 2003-07-21 2005-02-24 Medimmune, Inc. Combination therapy for the treatment and prevention of cancer using epha2, pcdgf, and haah
AU2004261603A1 (en) 2003-07-30 2005-02-10 Medimmune, Llc EphA2 T-cell epitope agonists and uses therefor
US20050048617A1 (en) 2003-08-18 2005-03-03 Medimmune, Inc. Humanization of antibodies
JP2007528723A (ja) 2003-08-22 2007-10-18 メディミューン，インコーポレーテッド 抗体のヒト化
WO2005037233A2 (en) 2003-10-15 2005-04-28 Medimmune, Inc. Listeria-based epha2 vaccines
DE10354115A1 (de) 2003-11-19 2005-07-21 Beiersdorf Ag Neue Verwendung von Tensidsystemen zur Verringerung der Schädigung hauteigener Enzyme
WO2005056766A2 (en) 2003-12-04 2005-06-23 Medimmune, Inc. TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES
WO2005067460A2 (en) 2003-12-24 2005-07-28 Medimmune, Inc. Epha2 vaccines
EP1745073A2 (en) 2004-05-14 2007-01-24 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
JP2008510008A (ja) 2004-08-16 2008-04-03 メディミューン，インコーポレーテッド 抗体依存性細胞性細胞傷害活性が増強されたインテグリンアンタゴニスト
WO2006052409A2 (en) 2004-10-23 2006-05-18 Case Western Reserve University Peptide and small molecule agonists of epha and their uses
WO2006047637A1 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Use of modulators of epha2 and ephrina1 for the treatment and prevention of infections
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
AU2005299354A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulators of EphA2 and ephrina1 for the treatment of fibrosis-related disease
CA2600844A1 (en) 2005-03-14 2006-09-21 Medimmune, Inc. Macromolecules comprising a thioether cross-link
CA2608512A1 (en) 2005-05-20 2007-02-15 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US8236772B2 (en) 2005-09-16 2012-08-07 The Board Of Trustees Of The Leland Stanford Junior University Methods of modulating angiogenesis and screening compounds for activity in modulating angiogenesis
WO2007075706A2 (en) * 2005-12-21 2007-07-05 Medimmune, Inc. Affinity optimized epha2 agonistic antibodies and methods of use thereof
CA2633713A1 (en) 2005-12-21 2007-06-28 Micromet Ag Epha2 bite molecules and uses thereof
BRPI0707679A2 (pt) 2006-02-01 2011-05-10 Tjhe Johns Hopkins University conjugado de polipetÍdeo - Àcido nuclÉico para imunoprofilaxia ou imunoterapia para distérbios neoplÁsticos ou infecciosos
US20080003210A1 (en) 2006-03-13 2008-01-03 Medimmune, Inc. Non-human primate receptor tyrosine kinases
KR101571027B1 (ko) 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
MX2009000709A (es) 2006-07-18 2009-02-04 Sanofi Aventis Anticuerpo antagonista contra epha2 para el tratamiento de cancer.
JP2010511382A (ja) 2006-12-01 2010-04-15 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 癌関連タンパク質キナーゼ
US20100166746A1 (en) 2006-12-04 2010-07-01 Medlmmune Way High potency recombinant antibodies, methods for producing them and use in cancer therapy
WO2009008901A2 (en) 2006-12-15 2009-01-15 Case Western Reserve University Peptide and small molecule agonises of epa and their uses in diseases
US20080199426A1 (en) 2007-01-11 2008-08-21 Sukhatme Vikas P Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
AU2008238938A1 (en) 2007-04-13 2008-10-23 Cytopathfinder, Inc. Compound profiling method
US20100254996A1 (en) 2007-06-18 2010-10-07 Medimmune, Llc Synergistic treatment of cells that express epha2 and erbb2
US20120039870A9 (en) 2007-09-07 2012-02-16 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
WO2009052830A1 (en) 2007-10-22 2009-04-30 Genmab A/S Novel antibody therapies

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455030A (en) 1986-09-02 1995-10-03 Enzon Labs, Inc. Immunotheraphy using single chain polypeptide binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1990007861A1 (en) 1988-12-28 1990-07-26 Protein Design Labs, Inc. CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1995001438A1 (en) 1993-06-30 1995-01-12 Medical Research Council Sbp members with a chemical moiety covalently bound within the binding site; production and selection thereof
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
WO2001005950A2 (en) 1999-07-20 2001-01-25 Morphosys Ag Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
WO2002031140A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions
WO2003094859A2 (en) 2002-05-10 2003-11-20 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
WO2004061104A2 (en) 2003-01-07 2004-07-22 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
WO2006084226A2 (en) 2005-02-04 2006-08-10 Raven Biotechnologies, Inc. Antibodies that bind to epha2 and methods of use thereof
WO2007030642A2 (en) * 2005-09-07 2007-03-15 Medimmune, Inc. Toxin conjugated eph receptor antibodies

Non-Patent Citations (74)

* Cited by examiner, † Cited by third party
Title
"Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY
"Monoclonal Antibodies", 1980, PLENUM PRESS, pages: 365 - 367
"Strategies for Protein Purification and Characterization: A Laboratory Course Manual", 1996, COLD SPRING HARBOR LABORATORY PRESS
AMERICAN JOURNAL OF PATHOLOGY, vol. 163, 2003, pages 2271 - 2276
ANNU. REV. IMMUNOL, vol. 12, 1994, pages 433 - 455
ANNUAL REVIEW OF NEUROSCIENCE, vol. 21, 1998, pages 309 - 345
BARBARA, B.M.; STANLEY, M.S.: "Selected Methods in Cellular Immunology", 1980, W.H. FREEMAN AND COMPANY
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 320, 2004, pages 1096 - 1102
BLOOD, vol. 103, 2004, pages 2738 - 2743
CANCER RESEARCH, vol. 61, 2001, pages 2301 - 2306
CANCER RESEARCH, vol. 62, 2002, pages 2840 - 2847
CANCER RESEARCH, vol. 63, 2003, pages 7907 - 7912
CANCER SCIENCE, vol. 96, 2005, pages 42 - 47
CARLES-KINCH K. ET AL.: "Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior", CANCER RES., vol. 62, no. 10, 2002, pages 2840 - 2847, XP002904266 *
CARMEN, S. ET AL., BRIEFINGS IN FUNCTIONAL GENOMICS AND PROTEOMICS, vol. 1, no. 2, 2002, pages 189 - 203
CLINICAL CANCER RESEARCH, vol. 9, 2003, pages 613 - 618
COFFMAN KT ET AL.: "Differential EphA2 epitope display on normal versus malignant cells", CANCER RES., vol. 63, no. 22, 2003, pages 7907 - 7912, XP002993150 *
EDMAN, P. ET AL., EUR. J. BIOCHEM., vol. 1, 1967, pages 80
FEBS LETTERS, vol. 399, 1996, pages 1 - 8
GLUZMAN, Y, CELL, vol. 23, 1981, pages 175 - 182
GLUZMAN, Y., CELL, vol. 23, 1981, pages 175 - 182
HEINRICH, G. ET AL., J. EXP. MED., vol. 159, 1984, pages 417 - 435
HUSTON, J.S. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 85, 1988, pages 5879 - 5883
INTERNATIONAL JOURNAL OF CANCER, vol. 103, 2003, pages 657 - 663
JOURNAL OF CELL SCIENCE, vol. 117, 2004, pages 2037 - 2049
KABAT, E.A. ET AL., SEQUENCE OF PROTEINS OF IMMUNOLOGICAL INTEREST, vol. I, II, 1991
KABAT, E.A. ET AL., SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST, vol. I, II, 1991
KABAT, E.A.; MAYER, M.M.: "Experimental Immunochemistry", 1964, CHARLES C THOMAS PUBLISHER SPRINGFIELD
KABAT, E.A.; MAYER, M.M.; CHARLES C THOMAS: "Experimental Immunochemistry", 1964, SPRINGFIELD
KIEWLICH D. ET AL.: "Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth", NEOPLASIA, vol. 8, no. 1, 2006, pages 18 - 30, XP002535474 *
KOHLER ET AL., EUR. J. IMMUNOL., vol. 6, 1977, pages 511
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497
KUROIWA, Y. ET AL., NUCL. ACIDS RES., vol. 26, 1998, pages 3447 - 3448
METHODS IN ENZYMOLOGY, vol. 203, 1991, pages 121 - 153
MILLSTEIN ET AL., NATURE, vol. 305, 1983, pages 537 - 539
MILSTEIN ET AL., NATURE, vol. 266, 1977, pages 550
MOLECULAR AND CELLULAR BIOLOGY, vol. 10, 1990, pages 6316 - 6324
MOLECULAR CANCER RESEARCH, vol. 1, 2002, pages 79 - 87
MOLECULAR CANCER RESEARCH, vol. 3, 2005, pages 541 - 551
NATURE BIOTECHNOLOGY, vol. 23, 2005, pages 1126 - 1136
NATURE BIOTECHNOLOGY, vol. 23, 2005, pages 1137 - 1146
NATURE BIOTECHNOLOGY, vol. 23, no. 9, 2005, pages 1105 - 1116
NATURE MEDICINE, vol. 6, 2000, pages 443 - 446
NATURE, vol. 321, 1986, pages 522 - 525
NEOPLASIA, vol. 8, 2006, pages 18 - 30
NUC. ACID RES., vol. 29, 2001, pages 205 - 206
NUC. ACID RES., vol. 35, 2007, pages D301 - D303
ONCOGENE, vol. 19, 2000, pages 6043 - 6052
ONCOGENE, vol. 21, 2002, pages 7011 - 7026
ONCOGENE, vol. 23, 2004, pages 1448 - 1456
ONCOGENE, vol. 26, 2007, pages 3603 - 3613
ONCOGENE, vol. 26, 2007, pages 3661 - 3678
ONCOLOGY REPORTS, vol. 11, 2004, pages 605 - 611
PLUCKTHUN: "The Pharmacology of Monoclonal Antibodies", vol. 113, 1994, SPRINGER VERLAG, pages: 269 - 315
PROC. NATL. ACAD. SCI. U.S.A., vol. 81, 1984, pages 6851 - 6855
PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 10029 - 10033
QUEEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 10029 - 10033
SAIKI, R.K. ET AL., SCIENCE, vol. 239, 1988, pages 487 - 489
SAMBROOK, J.; FRITSCH, E.F.; MANIATIS, T.: "Molecular Cloning", 1989, COLD SPRING HARBOR LABORATORY PRESS
See also references of EP2199390A4
SIRIWARDENA, D. ET AL., OPHTHALMOLOGY, vol. 109, no. 3, 2002, pages 427 - 431
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 357, 2007, pages 39 - 51
THE PROSTATE, vol. 41, 1999, pages 275 - 280
THORNTON ET AL., J. MOL. BIOL., vol. 263, 1996, pages 800 - 815
TOMIZUKA, K. ET AL., NATURE GENETICS, vol. 16, 1997, pages 133 - 143
TOMIZUKA, K. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 722 - 727
URLAUB, G.; CHASIN, L.A., PROC. NATL. ACAD. SCI. U.S.A., vol. 77, 1980, pages 4126 - 4220
URLAUB, G.; CHASIN, L.A., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4126 - 4220
WALSH, NATURE, vol. 266, 1977, pages 495
WEIR, D.M.: "Handbook of Experimental Immunology", vol. I, II, I, 1978, BLACKWELL SCIENTIFIC PUBLICATIONS
WEIR, D.M.: "Handbook of Experimental Immunology", vol. I, II, I, 1987, BLACKWELL SCIENTIFIC PUBLICATIONS
WORMSTONE, I.M. ET AL., INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 43, no. 7, 2002, pages 2301 - 2308
YOSHIDA, H. ET AL.: "Animal Cell Technology: Basic and Applied Aspects", vol. 10, 1999, KLUWER ACADEMIC PUBLISHERS, pages: 69 - 73

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012008397A1 (ja) * 2010-07-12 2012-01-19 第一三共株式会社 抗ｅｐｈａ２抗体及びその用途
AU2011280893B2 (en) * 2010-07-22 2014-12-04 The Regents Of The University Of California Anti-tumor antigen antibodies and methods of use
AU2011280893C1 (en) * 2010-07-22 2016-02-04 The Regents Of The University Of California Anti-tumor antigen antibodies and methods of use
US9446125B2 (en) * 2010-07-22 2016-09-20 The Regents Of The University Of California, Berke Anti-EphA2 antibodies and methods of use thereof
RU2598711C2 (ru) * 2010-07-22 2016-09-27 Те Риджентс Оф Те Юниверсити Оф Калифорния Антитело к противоопухолевому антигену и способы применения
US10406225B2 (en) 2010-07-22 2019-09-10 The Regents Of The University Of California Anti-EphA2 antibodies and methods of use thereof
CN110198956A (zh) * 2017-01-23 2019-09-03 学校法人东洋大学 抗epha2抗体和使用该抗epha2抗体的epha2免疫检测
WO2018135653A1 (ja) 2017-01-23 2018-07-26 学校法人東洋大学 抗ｅｐｈａ２抗体及びこれを用いたｅｐｈａ２の免疫学的検出
WO2020050406A1 (ja) 2018-09-06 2020-03-12 第一三共株式会社 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート
EP4524154A2 (en) 2018-09-06 2025-03-19 Daiichi Sankyo Company, Limited Antibody-drug conjugates of cyclic dinucleotide derivatives
WO2022163846A1 (ja) 2021-02-01 2022-08-04 第一三共株式会社 抗体－免疫賦活化剤コンジュゲートの新規製造方法
WO2022191313A1 (ja) 2021-03-12 2022-09-15 第一三共株式会社 糖鎖及び糖鎖を含む医薬品の製造方法
CN115505041A (zh) * 2021-06-22 2022-12-23 北京免疫方舟医药科技有限公司 抗EphA2抗体及其应用
WO2023167238A1 (ja) 2022-03-02 2023-09-07 第一三共株式会社 Ｆｃ含有分子の製造方法
WO2024053574A1 (ja) 2022-09-09 2024-03-14 第一三共株式会社 新規なオリゴ糖、該オリゴ糖の製造中間体、及びそれらの製造方法

Also Published As

Publication number Publication date
KR101561416B1 (ko) 2015-10-16
KR20150041186A (ko) 2015-04-15
ES2618316T3 (es) 2017-06-21
HUE032301T2 (en) 2017-09-28
CN101848998B (zh) 2016-08-03
RU2525133C2 (ru) 2014-08-10
CN101848998A (zh) 2010-09-29
US20160031987A1 (en) 2016-02-04
BRPI0816094A2 (pt) 2015-03-03
MY150621A (en) 2014-02-14
EP2199390A4 (en) 2012-12-12
KR20150041811A (ko) 2015-04-17
SI2199390T1 (sl) 2017-02-28
EP2199390B1 (en) 2016-12-21
RU2010111896A (ru) 2011-10-10
EP2199390A1 (en) 2010-06-23
CY1118763T1 (el) 2017-07-12
PL2199390T3 (pl) 2017-06-30
TW200916480A (en) 2009-04-16
KR101561403B1 (ko) 2015-10-16
MX2010002248A (es) 2010-03-25
KR20150008931A (ko) 2015-01-23
KR101521668B1 (ko) 2015-05-28
KR101561417B1 (ko) 2015-10-16
US20100183618A1 (en) 2010-07-22
CO6180469A2 (es) 2010-07-19
JPWO2009028639A1 (ja) 2010-12-02
JP5688433B2 (ja) 2015-03-25
US8449882B2 (en) 2013-05-28
TWI443109B (zh) 2014-07-01
CA2698146A1 (en) 2009-03-05
US9150657B2 (en) 2015-10-06
AU2008292352B2 (en) 2012-03-08
NZ583966A (en) 2012-04-27
ZA201001340B (en) 2010-11-24
LT2199390T (lt) 2017-03-10
US20140212439A1 (en) 2014-07-31
JP2013198492A (ja) 2013-10-03
DK2199390T3 (en) 2017-04-03
PT2199390T (pt) 2017-03-15
HRP20170407T1 (hr) 2017-05-05
AU2008292352A1 (en) 2009-03-05
KR20100057018A (ko) 2010-05-28
IL204211A (en) 2016-04-21
JP5312333B2 (ja) 2013-10-09
CA2698146C (en) 2016-12-20

Similar Documents

Publication Publication Date Title
WO2009028639A1 (ja) 抗ｅｐｈａ２抗体
WO2007115049A3 (en) Humanized monoclonal antibodies to hepatocyte growth factor
WO2008070344A3 (en) Compositions and methods for binding sphingosine-1-phosphate
NZ572756A (en) Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody
WO2009071696A3 (en) Humanized antibody molecules specific for il-31
WO2007117505A3 (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP2152754B8 (en) Monoclonal antibodies against claudin-18 for treatment of cancer
MX2014001373A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
IL202102A0 (en) Use of a monoclonal, chimeric humanized or human antibody that binds il-5r in the manufacture of a medicament for reducing eosinophil levels
IL196470A0 (en) Antagonist antibody against epha2 for the treatment of cancer
WO2007000671A3 (en) Anti-cd71 monoclonal antibodies and uses thereof for treating malignant tumour cells
SG10201504662WA (en) Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
WO2007056539A3 (en) Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
WO2006084264A3 (en) Cd20 antibody variants and uses thereof
MXPA06002890A (es) Anticuerpo antiglipicano 3.
IL184152A (en) Monoclonal antibodies against nkg2a, preparations containing them, their use in drug preparation, methods of manufacture, and methods used in
WO2009135861A3 (en) Humanized antibodies against human interferon-alpha
WO2008110379A8 (en) Monoclonal antibodies for treatment of cancer
NZ595863A (en) Antibodies to egfl7 and methods for their use
WO2008019326A3 (en) Ephb3-specific antibody and uses thereof
WO2008110914A3 (en) Methods for producing active scfv antibodies and libraries therefor
WO2010079510A3 (en) Anti-rhd monoclonal antibodies
WO2008030564A3 (en) Aglycosylated antibodies and methods of making and using those antibodies

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880114621.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08828482

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009530190

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107004260

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 727/KOLNP/2010

Country of ref document: IN

Ref document number: MX/A/2010/002248

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2698146

Country of ref document: CA

Ref document number: 12010500462

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 204211

Country of ref document: IL

REEP Request for entry into the european phase

Ref document number: 2008828482

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008828482

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 10028981

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 583966

Country of ref document: NZ

Ref document number: 2008292352

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PI 2010000815

Country of ref document: MY

WWE Wipo information: entry into national phase

Ref document number: 2010111896

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2008292352

Country of ref document: AU

Date of ref document: 20080829

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0816094

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100226